scholarly journals Evaluating the efficacy of current clinical practice of adjuvant chemotherapy in postmenopausal women with early-stage, estrogen or progesterone receptor–positive, one-to-three positive axillary lymph node, breast cancer

2012 ◽  
Vol 19 (5) ◽  
Author(s):  
M.B. Hannouf ◽  
M. Brackstone ◽  
B. Xie ◽  
G.S. Zaric
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Clinical Practice ◽  
Adjuvant Chemotherapy ◽  
Progesterone Receptor ◽  
Postmenopausal Women ◽  
Axillary Lymph Node ◽  
Early Stage ◽  
Axillary Lymph ◽  
Current Clinical Practice

Effect of Cognitive-Existential Group Therapy on Survival in Early-Stage Breast Cancer

2004 ◽  
Vol 22 (21) ◽  
pp. 4255-4260 ◽  
Author(s):  
David W. Kissane ◽  
Anthony Love ◽  
Allison Hatton ◽  
Sidney Bloch ◽  
Graeme Smith ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Group Therapy ◽  
Axillary Lymph Node ◽  
Early Stage ◽  
Hazard Ratio ◽  
Early Stage Breast Cancer ◽  
Lymph Node Status ◽  
Axillary Lymph

Purpose Cognitive-existential group therapy (CEGT) was developed to improve mood and mental attitude toward cancer in women with early-stage breast cancer receiving adjuvant chemotherapy. Given the debate about group therapy's association with increased survival in women with metastatic breast cancer, we were curious to check its effect at a much earlier stage in the cancer journey. Patients and Methods We randomly assigned 303 women with early-stage breast cancer who were receiving adjuvant chemotherapy to either 20 sessions of weekly group therapy plus three relaxation classes (n = 154) or to a control condition of three relaxation classes alone (n = 149). The primary outcome was survival. Results CEGT did not extend survival; the median survival time was 81.9 months (95% CI, 64.8 to 99.0 months) in the group-therapy women and 85.5 months (95% CI, 67.5 to 103.6 months) in the control arm. The hazard ratio for death was 1.35 (95% CI, 0.76 to 2.39; P = .31). In contrast, histology and axillary lymph node status were significant predictors of survival. Low-grade histology yielded a hazard ratio of 0.342 (95% CI, 0.17 to 0.69), and axillary lymph node–negative status yielded a hazard ratio of 0.397 (95% CI, 0.20 to 0.78). Conclusion CEGT does not prolong survival in women with early-stage breast cancer.

scholarly journals MicroRNA-1291 Is Associated With Locoregional Metastases in Patients With Early-Stage Breast Cancer

2020 ◽  
Vol 11 ◽  
Author(s):  
Daniel Escuin ◽  
Laura López-Vilaró ◽  
Olga Bell ◽  
Josefina Mora ◽  
Antonio Moral ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Signaling Pathways ◽  
Axillary Lymph Node ◽  
Target Genes ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Axillary Lymph ◽  
Illumina Platform ◽  
Down Regulation

Evidence that microRNAs (miRNAs) regulate the various steps of metastasis is increasing. Several studies have looked at the miRNA expression profile in primary breast tumors but few have compared primary tumor and sentinel lymph node (SLN) metastasis. We correlated the expression of miRNAs with the SLN status and the outcome of axillary lymph node dissection (ALND) in 60 patients with early breast cancer. We profiled the expression of miRNAs in paired breast tumor samples and SLNs using the NextSeq500 Illumina platform and key findings were validated by qPCR. MultiMiR Bioconductor and Reactome pathways analysis were performed to identify target genes and signaling pathways affected by altered expressed miRNAs. Our results show that nine miRNAs were differentially expressed in tumor tissues (q ≤ 0.05). In tumor samples, a 13.5-fold up-regulation of miR-7641-2 (q < 0.001) and a 2.9-fold down-regulation of miR-1291 (q < 0.001) were associated with tumors with positive SLNs. However, only down-regulation of miR-1291 (q = 0.048) remained significant in paired SLNs samples. Interestingly, a 10.5 up-regulation of miR-1291 in SLNs samples was associated with additional axillary lymph node involvement (q < 0.001). The enrichment analyses showed that canonical and non-canonical WNT pathways and negative regulation of various receptor tyrosine kinases signaling pathways were targets of miR-1291 and supports the role of miR-1291 as a tumor suppressor gene (TSG). Further studies are warranted to investigate the use of miR-1291 as a surrogate biomarker of SLN node metastasis in patients with early-stage breast cancer.

scholarly journals The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype

2017 ◽  
Vol 24 (12) ◽  
pp. 3527-3533 ◽  
Author(s):  
Melissa Pilewskie ◽  
Emily C. Zabor ◽  
Anita Mamtani ◽  
Andrea V. Barrio ◽  
Michelle Stempel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Axillary Lymph Node ◽  
Early Stage ◽  
Treatment Plan ◽  
Axillary Lymph ◽  
Tumor Subtype ◽  
Breast Cancer Patients ◽  
Node Dissection

scholarly journals Age and axillary lymph node ratio in postmenopausal women with T1-T2 node positive breast cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e11004-e11004
Author(s):  
B. H. Ly ◽  
V. Vinh-Hung ◽  
S. A. Joseph ◽  
N. Coutty ◽  
G. Vlastos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Postmenopausal Women ◽  
Axillary Lymph Node ◽  
Lymph Node Ratio ◽  
Axillary Lymph ◽  
Node Positive ◽  
Node Ratio ◽  
Positive Breast Cancer

scholarly journals Machine learning magnetic resonance imaging radiomics predicts axillary lymph node metastasis in invasive breast cancer

2020 ◽  
Author(s):  
Yunfang Yu ◽  
Zifan He ◽  
Jie Ouyang ◽  
Yujie Tan ◽  
Yong-Jian Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance Imaging ◽  
Machine Learning ◽  
Lymph Node ◽  
Clinical Practice ◽  
Magnetic Resonance ◽  
Invasive Breast Cancer ◽  
Axillary Lymph Node ◽  
Axillary Lymph ◽  
Resonance Imaging

Abstract In current clinical practice, the standard evaluation for axillary lymph node (ALN) status in breast cancer is based on the invasive procedure and many patients will suffer from operative associated complications. Hence, a novel signature incorporated tumor and lymph node magnetic resonance imaging (MRI) radiomics, clinical and pathological characteristics, and molecular subtypes based on the machine learning approach was established to accurately identify ALN metastasis in early-stage invasive breast cancer patients. Although the misjudgment of ALN status by clinicians according to preoperative MRI are common during clinical practice and even the senior radiologists make mistakes sometimes, this multiomic radiomic signature showed the superiority over clinicians and could precisely discriminate ALN metastasis among different molecular subtype patients. Furthermore, the association between MRI radiomic features and tumor-microenvironment features including immune cells, long non-coding RNAs, and types of methylated sites were found, which revealed the potential biological underpinning of MRI radiomics.

scholarly journals The St. Gallen 2019 Guidelines understages the Axilla in Lobular Breast Cancer a Population-Based Study

2021 ◽  
Author(s):  
Ulrik Narbe ◽  
Par-Ola Bendahl ◽  
Marten Ferno ◽  
Christian Ingvar ◽  
Looket Dihge ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Axillary Lymph Node ◽  
Study Cohort ◽  
Axillary Lymph ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
National Quality

Background The St. Gallen 2019 guidelines recommend omission of completion axillary lymph node dissection (cALND) in breast cancer patients with 1-2 sentinel lymph node (SLN) metastases regardless of histopathology. Concurrently, adjuvant chemotherapy is endorsed for luminal A-like disease with ≥4 axillary lymph node (ALN) metastases. We aimed to estimate the proportion of patients with invasive lobular cancer (ILC) and invasive ductal cancer of no special type (NST) and 1-2 SLN metastases for whom cALND would indicate need of adjuvant chemotherapy. Methods Patients with ILC and NST histopathology undergoing primary surgery 2014-2017 were identified in the Swedish National Quality Breast Cancer register. After exclusion of patients with incongruent or missing data, 1886 patients who fulfilled the St. Gallen 2019 criteria for cALND omission were included in the study cohort. Results Patients with ILC (n = 329) had a higher metastatic nodal burden and more often a luminal A-like subtype compared with NST patients (n = 1507). The prevalence of ≥ 4 ALN metastases was higher in ILC (31%) than in NST (15%), corresponding to an adjusted odds of 2.26 (95% CI 1.59-3.21). Luminal A-like breast cancers with ≥4 ALN metastases were overrepresented in ILC cases (52/281 (19%)) compared to NST cases (43/1299 (3%)), P<0.001. Conclusions Patients with ILC more often had a luminal A-like breast cancer with ≥4 ALN metastases compared with NST patients. Abstaining cALND in patients with luminal A-like ILC with 1-2 SLN metastases warrants future attention as it risks nodal understaging and hence undertreatment in one-fifth of these patients.

Sign in / Sign up

Export Citation Format

Share Document